CalciMedica, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
CALC$1.37-9.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except par value and share amounts)
| September 30,2026 | December 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $4,574 | $11,520 |
| Short-term investments | 9,194 | 1,496 |
| Prepaid clinical trial expenses | 18 | 201 |
| Other prepaid expenses and current assets | 432 | 259 |
| Assets held for sale | — | 54 |
| Total current assets | 14,218 | 13,530 |
| Property and equipment, net | 72 | 50 |
| Other assets | 4 | 11 |
| Total assets | $14,294 | $13,591 |
| Liabilities and Stockholders’ Equity (Deficit) | ||
| Current liabilities | ||
| Accounts payable | $1,020 | $1,161 |
| Accrued clinical trial costs | 226 | 1,081 |
| Accrued expenses | 1,621 | 290 |
| Current portion, promissory note | — | 1,250 |
| Total current liabilities | 2,867 | 3,782 |
| Long-term liabilities | ||
| Promissory note | 6,900 | 8,450 |
| Warrant liability | 300 | 8,000 |
| Total liabilities | 10,067 | 20,232 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity (deficit) | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2026 and December 31, 2025, respectively; no shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | — | — |
| Common stock, $0.0001 par value; 100,000,000 and 500,000,000 shares authorized at September 30, 2026 and December 31, 2025, respectively; 6,894,649 and 3,087,348 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 1 | — |
| Additional paid-in capital | 197,909 | 182,685 |
| Accumulated deficit | (193,676) | (189,326) |
| Accumulated other comprehensive loss | (7) | — |
| Total stockholders’ equity (deficit) | 4,227 | (6,641) |
| Total liabilities and stockholders’ equity (deficit) | $14,294 | $13,591 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.